Jonathan G. Moggs

Basel, BS, Switzerland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 44 publications

Correction: The potent human CAR activator CITCO is a non-genotoxic hepatic tumour-promoting agent in humanised constitutive androstane receptor mice but not in wild-type animals.

Correction: The potent human CAR activator CITCO is a non-genotoxic hepatic tumour-promoting agent in humanised constitutive androstane receptor mice but not in wild-type animals.

Journal: Archives of toxicology
Published: June 26, 2026

Innovative Medicines Initiative public-private partnerships to enhance translational safety.

Innovative Medicines Initiative public-private partnerships to enhance translational safety.

Journal: Nature reviews. Drug discovery
Published: May 22, 2025

The potent human CAR activator CITCO is a non-genotoxic hepatic tumour-promoting agent in humanised constitutive androstane receptor mice but not in wild-type animals.

The potent human CAR activator CITCO is a non-genotoxic hepatic tumour-promoting agent in humanised constitutive androstane receptor mice but not in wild-type animals.

Journal: Archives of toxicology
Published: January 16, 2025

Novel strategies to assess cytokine release mediated by chimeric antigen receptor T cells based on the adverse outcome pathway concept.

Novel strategies to assess cytokine release mediated by chimeric antigen receptor T cells based on the adverse outcome pathway concept.

Journal: Journal of immunotoxicology
Published: December 10, 2024

Unaltered hepatic wound healing response in male rats with ancestral liver injury.

Unaltered hepatic wound healing response in male rats with ancestral liver injury.

Journal: Nature communications
Published: November 09, 2022

Using human genetics to improve safety assessment of therapeutics.

Using human genetics to improve safety assessment of therapeutics.

Journal: Nature reviews. Drug discovery
Published: September 02, 2022

Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies.

Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies.

Journal: Journal of medicinal chemistry
Published: March 30, 2022

Correction: The genetic consequences of dog breed formation-Accumulation of deleterious genetic variation and fixation of mutations associated with myxomatous mitral valve disease in cavalier King Charles spaniels.

Correction: The genetic consequences of dog breed formation-Accumulation of deleterious genetic variation and fixation of mutations associated with myxomatous mitral valve disease in cavalier King Charles spaniels.

Journal: PLoS genetics
Published: January 27, 2022

The genetic consequences of dog breed formation-Accumulation of deleterious genetic variation and fixation of mutations associated with myxomatous mitral valve disease in cavalier King Charles spaniels.

The genetic consequences of dog breed formation-Accumulation of deleterious genetic variation and fixation of mutations associated with myxomatous mitral valve disease in cavalier King Charles spaniels.

Journal: PLoS genetics
Published: March 17, 2021

Outcomes of the European Federation of Pharmaceutical Industries and Associations Oligonucleotide Working Group Survey on Nonclinical Practices and Regulatory Expectations for Therapeutic Oligonucleotide Safety Assessment.

Outcomes of the European Federation of Pharmaceutical Industries and Associations Oligonucleotide Working Group Survey on Nonclinical Practices and Regulatory Expectations for Therapeutic Oligonucleotide Safety Assessment.

Journal: Nucleic acid therapeutics
Published: October 15, 2020

Nonclinical safety assessment of epigenetic modulatory drugs: Current status and industry perspective.

Nonclinical safety assessment of epigenetic modulatory drugs: Current status and industry perspective.

Journal: Regulatory toxicology and pharmacology : RTP
Published: April 20, 2020

A cross-sector call to improve carcinogenicity risk assessment through use of genomic methodologies.

A cross-sector call to improve carcinogenicity risk assessment through use of genomic methodologies.

Journal: Regulatory toxicology and pharmacology : RTP
Published: July 17, 2019
Showing 1-12 of 44

Last Updated: 09/26/2026